Developer docs
API playgroundTry for free, no card

Search company profiles

AlphaMol

Full company profile

uuid000a4dc

Namestring
AlphaMol
Legal namestring
ALPHAMOL SCIENCE LTD
Websiteurl
alphamol.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

AlphaMol is a biopharmaceutical company founded in 2020 and headquartered in Allschwil (Basel), Switzerland, with regional offices in Shanghai and an R&D office in Shenzhen, China. The company operates a dual-entity structure consisting of AlphaMol Science Ltd. (Switzerland) and Alpha Molecular Technology Co., Ltd. (China). Its core business is G-protein-coupled receptor (GPCR)-targeted drug discovery and development, supported by the proprietary GPCR-Discovery AI platform that integrates computational biology, artificial intelligence, and biotechnology across modules including GPCR-GPT (target identification), GPCR-3D (structure prediction), Alpha-screen (functional screening), GPCRomx (ligand selectivity), GPCR-lead (optimization), GPCR-XDC (peptide-drug conjugate design), and AlphaE (binding energy prediction with validated 1 kcal/mol RMSE).

The company's pipeline includes AM-001, an oral small molecule targeting MRGPRX2 for autoimmune diseases (atopic dermatitis, urticaria), which received IND approval from both the Chinese CDE and US FDA in June 2025; a non-opioid painkiller program with biased mu-opioid receptor agonists; and metabolism programs (oral small molecule and peptide). AlphaMol generates revenue through co-development partnerships and out-licensing deals with pharmaceutical companies, though no commercial revenue is currently disclosed. The company completed a Series A financing round in August 2023 with investors including Huaqiang Capital, New Value Capital, and Shanghai Biomedical Industrial Equity Investment Fund.

Co-founders Dr. Shuguang Yuan and Prof. Horst Vogel anchor the scientific leadership, both recognized in Stanford's Top 2% Scientists globally. Dr. Yuan previously advanced two GPCR candidates to clinical development at Actelion, with one achieving FDA approval. Dr. Vogel is a full professor at EPFL with 40+ years of GPCR research and affiliations with Roche, Novartis, and Nestlé. AlphaMol has established research collaborations with the Max Planck Institute and Chinese Academy of Sciences, and its team won the 4th global GPCR-DOCK contest in 2022.

Short descriptiontext

AlphaMol is a biopharmaceutical company operating across Switzerland and China that uses its proprietary AI-driven GPCR-Discovery platform to develop drug candidates for autoimmune, metabolism, and pain conditions, targeting pharmaceutical partnership and licensing deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersShenzhen, China
HQ citystring
Shenzhen
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GPCR drug discovery, AI drug design, computational biology platform, preclinical drug development, biopharma research
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development Partnerships and Licensing
TypeLicensing Royalties
Description

AlphaMol generates revenue through co-development partnerships with pharmaceutical companies, out-licensing of drug candidates, and strategic collaborations. The company has progressed pipeline candidate AM-001 to IND approval and is advancing toward clinical trials, positioning for potential licensing deals or partnership structures with larger pharmaceutical companies.

alphamol.com
2Series A Financing
TypeSubscription Recurring
Description

Venture capital funding to support drug development and biotechnology research operations. Series A round completed in August 2023.

equalocean.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1GPCRomx
Description

Platform for predicting ligand selectivity in GPCR drug discovery

alphamol.com
+2 more records
Core offering1 text field

AlphaMol operates the GPCR-Discovery AI platform, an integrated software-driven drug discovery system for G-protein-coupled receptor (GPCR) drug development that combines molecular generation, virtual screening, lead optimization, molecular dynamics simulation, and binding energy prediction. In parallel, the company develops its own GPCR-targeted drug candidates (including AM-001 for autoimmune diseases, which has received IND approval from both Chinese CDE and the U.S. FDA) and engages in co-development partnerships and out-licensing of drug candidates with pharmaceutical and biotech companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 80-99% cost savings in drug discovery time and finance compared to traditional methods
+4 more records
Product overview1 text field

AlphaMol is an innovative biotech company combining computational biology, artificial intelligence, and cutting-edge biotechnology to advance GPCR (G-protein-coupled receptor) drug discovery. The company operates the GPCR-Discovery platform, a comprehensive AI-driven system with multiple integrated modules including GPCR-GPT (target identification), GPCR-3D (structure prediction), Alpha-screen (functional screening), GPCRomx (ligand selectivity prediction), GPCR-lead (lead optimization), and GPCR-XDC (peptide-drug conjugate design). Supporting tools include AlphaE for binding energy prediction. The company also develops in-house drug candidates, including AM-001 (an oral small molecule for autoimmune diseases now in clinical stages with IND approval). Pipelines span autoimmune, metabolism, and pain management therapeutic areas. AlphaMol has sites in Basel (Switzerland), Shanghai, and Shenzhen (China).

Product and service2 records
1GPCR-Discovery Platform
CategoryDrug Discovery Software Platform
Description

An AI-driven drug discovery platform specifically designed for GPCR drug development. The platform integrates computational biology, artificial intelligence, and biotechnology through multiple modules covering target identification, structure prediction, functional screening, ligand selectivity prediction, lead optimization, and peptide-drug conjugate design. It enables completion of preclinical drug discovery in 6–12 months versus traditional 12+ year timelines, with claimed 80–99% cost savings. Targeted at pharmaceutical and biotech companies and internal pipeline development.

2AM-001
CategoryDrug Candidate (Therapeutic Pipeline)
Description

Oral small molecule drug candidate developed by AlphaMol targeting the MRGPRX2 receptor for the treatment of autoimmune diseases, including atopic dermatitis and urticaria. Demonstrated >600-fold safety margin in GLP toxicology studies and verified in vivo efficacy in animal models. Received IND approval from both the Chinese CDE and the U.S. FDA in June 2025; intended for out-licensing and/or co-development with pharmaceutical partners.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-03
Description

AlphaMol Science Ltd collaborated with the Max Planck Institute in Germany to publish research on the serotonin-gated 5-HT3A receptor structure in The EMBO Journal. Professor Mikhail Kudryashev from Max Planck Institute served as corresponding author alongside AlphaMol scientists.

2CADD Center at Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-03
Description

Collaboration on research article titled 'Structure of Tetrameric Forms of the Serotonin-gated 5-HT3A Receptor Ion Channel' published in The EMBO Journal as cover story.

alphamol.com
3School of Pharmaceutical Sciences at Shenzhen University of Science and Technology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-03
Description

Collaboration on research article titled 'Structure of Tetrameric Forms of the Serotonin-gated 5-HT3A Receptor Ion Channel' published in The EMBO Journal as cover story.

alphamol.com
4Swiss Consulate General of Switzerland in Guangzhou
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-07-04
Description

AlphaMol co-founders were invited to attend dinner in honor of Swiss delegation visiting China on the 10th anniversary of the Bilateral Free Trade Agreement between China and Switzerland. Facilitated networking with Swiss Federal Council member Guy Parmelin and EPFL President.

alphamol.com
5Swiss Federal Institute of Technology (EPFL)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-04
Description

Professor Horst Vogel, co-founder of AlphaMol, is a full professor at EPFL and maintains ongoing collaboration. Professor Martin Vetterli, President of EPFL, engaged with AlphaMol co-founders regarding bilateral scientific cooperation between China and Switzerland.

alphamol.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public AI-driven computational drug discovery platform offering molecular simulation, predictive modeling, and collaborative drug discovery programs. Highly comparable to AlphaMol in its use of physics-based and ML methods to accelerate preclinical drug design, though at much greater scale and breadth.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutic targets and advance an internal pipeline. Comparable to AlphaMol as a platform-plus-pipeline biotech using computational tools to derisk early-stage discovery, though focused on phenotypic screening across multiple target classes rather than GPCR specialization.

TypeDirect peer
Description

ML-enabled drug discovery company combining induced pluripotent stem cell biology, high-throughput experimentation, and AI to accelerate therapeutic development. Comparable to AlphaMol in applying AI to drug discovery pipelines, though differentiated by its wet-lab biology scale and disease-agnostic approach.

TypeDirect peer
Description

China-based AI drug discovery company combining quantum physics, AI, and cloud computing for small molecule and crystal structure prediction. Highly comparable to AlphaMol as a fellow China-rooted AI drug discovery company with international operations and shared computational methodology, though XtalPi has broader therapeutic and partner scope.

TypeDirect peer
Description

AI-driven precision medicine and drug discovery company that has brought multiple AI-designed candidates into clinical trials. Comparable to AlphaMol as a generative AI-first drug discovery company, with proven pharma partnerships (e.g., Bristol-Myers Squibb, Sanofi) but broader target coverage.

6Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company building a computational platform for novel drug design with major pharma partnerships (Eli Lilly, Novartis). Comparable to AlphaMol in its AI-first approach to drug discovery, but operates at vastly greater scale, capital base, and target breadth as a subsidiary of a global technology leader.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and advance internal and partnered programs. Comparable to AlphaMol in applying AI to drug discovery with both platform and pipeline components, though with a broader target and indication focus.

TypeEmerging player
Description

Clinical-stage biotech focused on oral small molecule GPCR-targeted therapeutics for metabolic and cardiopulmonary diseases. Comparable to AlphaMol as a GPCR-focused drug developer, though Structure Therapeutics is more clinically advanced and focuses exclusively on oral small molecules rather than a broader AI platform approach.

TypeDirect peer
Description

AI-driven small molecule drug discovery company using deep learning for structure-based design and virtual screening across multiple therapeutic areas. Comparable to AlphaMol in leveraging AI for hit identification and lead optimization, though without a GPCR-specific focus and with a stronger emphasis on pharma partnerships.

TypeBroad incumbent
Description

Technology-enabled drug development company that acquires and advances clinical-stage therapeutic programs across multiple disease areas. Comparable to AlphaMol as a platform-centric drug developer pursuing partnership and licensing economics, though at a larger scale and later development stage across multiple modalities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AlphaMol

AI Drug Discovery Platformalphamol.com

AlphaMol is a biopharmaceutical company operating across Switzerland and China that uses its proprietary AI-driven GPCR-Discovery platform to develop drug candidates for autoimmune, metabolism, and pain conditions, targeting pharmaceutical partnership and licensing deals.

What AlphaMol does

AlphaMol is a biopharmaceutical company founded in 2020 and headquartered in Allschwil (Basel), Switzerland, with regional offices in Shanghai and an R&D office in Shenzhen, China. The company operates a dual-entity structure consisting of AlphaMol Science Ltd. (Switzerland) and Alpha Molecular Technology Co., Ltd. (China). Its core business is G-protein-coupled receptor (GPCR)-targeted drug discovery and development, supported by the proprietary GPCR-Discovery AI platform that integrates computational biology, artificial intelligence, and biotechnology across modules including GPCR-GPT (target identification), GPCR-3D (structure prediction), Alpha-screen (functional screening), GPCRomx (ligand selectivity), GPCR-lead (optimization), GPCR-XDC (peptide-drug conjugate design), and AlphaE (binding energy prediction with validated 1 kcal/mol RMSE).

The company's pipeline includes AM-001, an oral small molecule targeting MRGPRX2 for autoimmune diseases (atopic dermatitis, urticaria), which received IND approval from both the Chinese CDE and US FDA in June 2025; a non-opioid painkiller program with biased mu-opioid receptor agonists; and metabolism programs (oral small molecule and peptide). AlphaMol generates revenue through co-development partnerships and out-licensing deals with pharmaceutical companies, though no commercial revenue is currently disclosed. The company completed a Series A financing round in August 2023 with investors including Huaqiang Capital, New Value Capital, and Shanghai Biomedical Industrial Equity Investment Fund.

Co-founders Dr. Shuguang Yuan and Prof. Horst Vogel anchor the scientific leadership, both recognized in Stanford's Top 2% Scientists globally. Dr. Yuan previously advanced two GPCR candidates to clinical development at Actelion, with one achieving FDA approval. Dr. Vogel is a full professor at EPFL with 40+ years of GPCR research and affiliations with Roche, Novartis, and Nestlé. AlphaMol has established research collaborations with the Max Planck Institute and Chinese Academy of Sciences, and its team won the 4th global GPCR-DOCK contest in 2022.

AlphaMol firmographics

Firmographics
Name
AlphaMol
Legal name
ALPHAMOL SCIENCE LTD
Website
https://alphamol.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
AlphaMol is a biopharmaceutical company operating across Switzerland and China that uses its proprietary AI-driven GPCR-Discovery platform to develop drug candidates for autoimmune, metabolism, and pain conditions, targeting pharmaceutical partnership and licensing deals.
Ownership category
akta.pro rank

AlphaMol industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • GPCR drug discovery
  • AI drug design
  • Computational biology platform
  • Preclinical drug development
  • Biopharma research

Where AlphaMol is headquartered

Location

Headquarters

HQ city
Shenzhen
HQ country
China
HQ region
Asia

Offices4 records

Markets served

AlphaMol business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D

Revenue model

  1. Drug Development Partnerships and Licensing: AlphaMol generates revenue through co-development partnerships with pharmaceutical companies, out-licensing of drug candidates, and strategic collaborations. The company has progressed pipeline candidate AM-001 to IND approval and is advancing toward clinical trials, positioning for potential licensing deals or partnership structures with larger pharmaceutical companies.
  2. Series A Financing: Venture capital funding to support drug development and biotechnology research operations. Series A round completed in August 2023.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

AlphaMol product offering

Product offering

Core offering

AlphaMol operates the GPCR-Discovery AI platform, an integrated software-driven drug discovery system for G-protein-coupled receptor (GPCR) drug development that combines molecular generation, virtual screening, lead optimization, molecular dynamics simulation, and binding energy prediction. In parallel, the company develops its own GPCR-targeted drug candidates (including AM-001 for autoimmune diseases, which has received IND approval from both Chinese CDE and the U.S. FDA) and engages in co-development partnerships and out-licensing of drug candidates with pharmaceutical and biotech companies.

Product overview

AlphaMol is an innovative biotech company combining computational biology, artificial intelligence, and cutting-edge biotechnology to advance GPCR (G-protein-coupled receptor) drug discovery. The company operates the GPCR-Discovery platform, a comprehensive AI-driven system with multiple integrated modules including GPCR-GPT (target identification), GPCR-3D (structure prediction), Alpha-screen (functional screening), GPCRomx (ligand selectivity prediction), GPCR-lead (lead optimization), and GPCR-XDC (peptide-drug conjugate design). Supporting tools include AlphaE for binding energy prediction. The company also develops in-house drug candidates, including AM-001 (an oral small molecule for autoimmune diseases now in clinical stages with IND approval). Pipelines span autoimmune, metabolism, and pain management therapeutic areas. AlphaMol has sites in Basel (Switzerland), Shanghai, and Shenzhen (China).

Differentiator

Problem solved

Functional benefit

Brands

  • GPCRomx: Platform for predicting ligand selectivity in GPCR drug discovery
  • GPCR-Discovery
  • AlphaE

Products and services

  • GPCR-Discovery Platform An AI-driven drug discovery platform specifically designed for GPCR drug development. The platform integrates computational biology, artificial intelligence, and biotechnology through multiple modules covering target identification, structure prediction, functional screening, ligand selectivity prediction, lead optimization, and peptide-drug conjugate design. It enables completion of preclinical drug discovery in 6–12 months versus traditional 12+ year timelines, with claimed 80–99% cost savings. Targeted at pharmaceutical and biotech companies and internal pipeline development.
  • AM-001 Oral small molecule drug candidate developed by AlphaMol targeting the MRGPRX2 receptor for the treatment of autoimmune diseases, including atopic dermatitis and urticaria. Demonstrated >600-fold safety margin in GLP toxicology studies and verified in vivo efficacy in animal models. Received IND approval from both the Chinese CDE and the U.S. FDA in June 2025; intended for out-licensing and/or co-development with pharmaceutical partners.

Quantifiable outcome

  • 80-99% cost savings in drug discovery time and finance compared to traditional methods
  • +4 more outcomes

Companies that use AlphaMol

Customer profile

Segments2 records

Ideal customer profiles1 record

AlphaMol technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

AlphaMol partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Max Planck Institute (Germany)coreStrategic or Co-development Partner · 3 September 2024AlphaMol Science Ltd collaborated with the Max Planck Institute in Germany to publish research on the serotonin-gated 5-HT3A receptor structure in The EMBO Journal. Professor Mikhail Kudryashev from Max Planck Institute served as corresponding author alongside AlphaMol scientists.
  • CADD Center at Shenzhen Institutes of Advanced Technology, Chinese Academy of SciencescoreStrategic or Co-development Partner · 3 September 2024Collaboration on research article titled 'Structure of Tetrameric Forms of the Serotonin-gated 5-HT3A Receptor Ion Channel' published in The EMBO Journal as cover story.
  • School of Pharmaceutical Sciences at Shenzhen University of Science and TechnologycoreStrategic or Co-development Partner · 3 September 2024Collaboration on research article titled 'Structure of Tetrameric Forms of the Serotonin-gated 5-HT3A Receptor Ion Channel' published in The EMBO Journal as cover story.
  • Swiss Consulate General of Switzerland in GuangzhouminorGTM or Marketing Partner · 4 July 2024AlphaMol co-founders were invited to attend dinner in honor of Swiss delegation visiting China on the 10th anniversary of the Bilateral Free Trade Agreement between China and Switzerland. Facilitated networking with Swiss Federal Council member Guy Parmelin and EPFL President.
  • Swiss Federal Institute of Technology (EPFL)coreStrategic or Co-development Partner · 4 July 2024Professor Horst Vogel, co-founder of AlphaMol, is a full professor at EPFL and maintains ongoing collaboration. Professor Martin Vetterli, President of EPFL, engaged with AlphaMol co-founders regarding bilateral scientific cooperation between China and Switzerland.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

AlphaMol competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Public AI-driven computational drug discovery platform offering molecular simulation, predictive modeling, and collaborative drug discovery programs. Highly comparable to AlphaMol in its use of physics-based and ML methods to accelerate preclinical drug design, though at much greater scale and breadth.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutic targets and advance an internal pipeline. Comparable to AlphaMol as a platform-plus-pipeline biotech using computational tools to derisk early-stage discovery, though focused on phenotypic screening across multiple target classes rather than GPCR specialization.
  • Insitro: ML-enabled drug discovery company combining induced pluripotent stem cell biology, high-throughput experimentation, and AI to accelerate therapeutic development. Comparable to AlphaMol in applying AI to drug discovery pipelines, though differentiated by its wet-lab biology scale and disease-agnostic approach.
  • XtalPi: China-based AI drug discovery company combining quantum physics, AI, and cloud computing for small molecule and crystal structure prediction. Highly comparable to AlphaMol as a fellow China-rooted AI drug discovery company with international operations and shared computational methodology, though XtalPi has broader therapeutic and partner scope.
  • Exscientia: AI-driven precision medicine and drug discovery company that has brought multiple AI-designed candidates into clinical trials. Comparable to AlphaMol as a generative AI-first drug discovery company, with proven pharma partnerships (e.g., Bristol-Myers Squibb, Sanofi) but broader target coverage.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and advance internal and partnered programs. Comparable to AlphaMol in applying AI to drug discovery with both platform and pipeline components, though with a broader target and indication focus.
  • Atomwise: AI-driven small molecule drug discovery company using deep learning for structure-based design and virtual screening across multiple therapeutic areas. Comparable to AlphaMol in leveraging AI for hit identification and lead optimization, though without a GPCR-specific focus and with a stronger emphasis on pharma partnerships.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company building a computational platform for novel drug design with major pharma partnerships (Eli Lilly, Novartis). Comparable to AlphaMol in its AI-first approach to drug discovery, but operates at vastly greater scale, capital base, and target breadth as a subsidiary of a global technology leader.
  • Roivant Sciences: Technology-enabled drug development company that acquires and advances clinical-stage therapeutic programs across multiple disease areas. Comparable to AlphaMol as a platform-centric drug developer pursuing partnership and licensing economics, though at a larger scale and later development stage across multiple modalities.

Emerging players

  • Structure Therapeutics: Clinical-stage biotech focused on oral small molecule GPCR-targeted therapeutics for metabolic and cardiopulmonary diseases. Comparable to AlphaMol as a GPCR-focused drug developer, though Structure Therapeutics is more clinically advanced and focuses exclusively on oral small molecules rather than a broader AI platform approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AlphaMol social profiles

Digital presence

AlphaMol financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AlphaMol leadership team

Management profile

Number of profiles

Profiles2 records

AlphaMol funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AlphaMol M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlphaMol

What does AlphaMol do?

AlphaMol operates the GPCR-Discovery AI platform, an integrated software-driven drug discovery system for G-protein-coupled receptor (GPCR) drug development that combines molecular generation, virtual screening, lead optimization, molecular dynamics simulation, and binding energy prediction. In parallel, the company develops its own GPCR-targeted drug candidates (including AM-001 for autoimmune diseases, which has received IND approval from both Chinese CDE and the U.S. FDA) and engages in co-development partnerships and out-licensing of drug candidates with pharmaceutical and biotech companies.

Is AlphaMol a public or private company?

AlphaMol is a private company. It is classified as venture growth investor backed and is currently operating.

When was AlphaMol founded?

AlphaMol was founded in 2020. It employs 1 to 10 people.

Where is AlphaMol based?

AlphaMol is headquartered in Shenzhen, China, in the Asia region.

How does AlphaMol make money?

Two revenue lines are on record. Drug Development Partnerships and Licensing is the primary driver. The others are series A Financing.

Who are AlphaMol's main competitors?

Direct peers on record are Schrödinger, Recursion Pharmaceuticals, Insitro, XtalPi, Exscientia, BenevolentAI and Atomwise. Broad incumbents are Isomorphic Labs and Roivant Sciences. Structure Therapeutics is listed as an emerging player.

Does AlphaMol have an API?

No public API is recorded for AlphaMol.

What industry is AlphaMol in?

AlphaMol's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals